Sai Parenteral's Ltd, a diversified pharmaceutical formulation company, garnered more than Rs 122 crore from anchor investors on Monday, a day before its initial public offering (IPO) opens for subscription.
Morgan Stanley Asia (Singapore) Pte Ltd, Kotak Lifesciences Fund, Quant Mutual Fund, Kotak Mahindra Life Insurance Company and India Emerging Giants Funds Ltd are the anchor investors, according to a circular uploaded on BSE's website.
The Hyderabad-based company has allotted 31,28,485 equity shares to these funds at Rs 392 apiece, which is also the IPO's upper price band. This aggregates the transaction size to Rs 122.63 crore.
The company's maiden public offering will open for subscription on March 24 and conclude on March 27.
The IPO comprises a fresh issue of up to Rs 285 crore and an offer-for-sale of up to nearly 32 lakh equity shares. The price band has been fixed at Rs 372-392 per share.
Proceeds from the IPO will support the firm's expansion, particularly in strengthening its global formulations business and expanding its Contract Development and manufacturing organisation capabilities across both injectable products and oral solid dosage formulations.
ALSO READ: Sai Parenteral IPO: What GMP Signals Ahead Of March 24 Opening
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
